M a n u s c r i p t
Introduction: Relationship between molecular biology and pathomorphology in thyroid cancer
Differentiated thyroid cancers derived from the follicular cell can be divided into two main types, papillary and follicular cancers. Papillary thyroid carcinoma (PTC) arises de novo from the follicular epithelial cell and is typically composed of papillary structures. Follicular cancers (FC) are morphologically similar to follicular adenomas, which are benign lesions.
Evidence of invasion through the capsule into veins or extra-thyroid tissues distinguishes follicular carcinoma from follicular adenoma. Diagnosis is made on a number of pathomorphological features characteristic for PTCs (e.g. grooved pale nuclei that frequently show intranuclear cytoplasmic inclusions and psammoma bodies which are calcified structures found within the tumours) that are lacking in follicular tumours. The diagnosis of PTC depends on the presence of a number of these features, but not all have to be present for a diagnosis of papillary cancer to be made (Al-Brahim and Asa 2006) .
In addition to the two main types of cancer derived from the follicular cells, there are a number of subtypes of both PTCs and FCs. These are named on the dominant structural component. Beside the above mentioned classic PTC, the most commonly found in adults is the follicular variant of PTC which is composed of follicular structures but has the nuclear features and psammoma bodies that are typical for papillary cancer. The solid or solid follicular variant of PTC is composed of solid sheets of cells with or without a follicular component. The latter variant shows variable nuclear features but does contain psammoma bodies. There are other, rarer subtypes of PTCs but these will not be further discussed in this review. FCs are subdivided on the basis of their follicular size -micro, normo or macrofollicular, and where there is a lack of follicular lumina and the morphology appears more solid, trabecular. For an excellent comprehensive review of follicular cell neoplasia, rather than just thyroid cancer, the reader is referred to Kondo et al. (2006) . PTC3since both partner genes, H4 and Ncoa4 are also located on chromosome 10. Initial studies reported that there was a higher than expected frequency of Ret rearrangement in PTC arising in the population exposed to radiation from the Chernobyl accident, suggesting some Ret rearrangements might be regarded as a marker for radiation exposure (Fugazzola, et al. 1995; Klugbauer, et al. 1995) . More recent papers have suggested that there is not a link between radiation exposure and Ret rearrangements since frequent RET/PTC rearrangements have also been observed in sporadic papillary carcinomas from children and young adults with a prevalence of 40 to 70% of cases (Tuttle, et al. 2008) . These findings may therefore reflect more the association between the solid morphological subtype with RET/PTC3 rearrangement and the age of the patient at diagnosis, rather than the aetiology of the tumour (Nikiforova, et al. 2004; Thomas, et al. 1999 ).
However, in contrast to the post-Chernobyl tumours radiation-associated thyroid tumours either as a result of exposure to radiation for therapeutic puposes (Bounacer, et al. 1997) or developed in the atomic bomb survivors (Hamatani, et al. 2008 )exhibited most frequently RET/PTC1 rearrangements. Altogether, these findings indicate that Ret rearrangements are not induced in each case by ionising radiation and therefore make RET/PTC as a radiationspecific marker in papillary thyroid carcinomas questionable, at the very least.
It is important to remember that the correlation between molecular biology and pathology is not absolute: in all of the series published so far, a substantial proportion (30%-50%) of papillary cancers do not harbour rearrangements of the Ret gene at all. A variety of different techniques have been used to assess the frequency of Ret rearrangements and, although this may explain the variation in frequency of Ret rearrangements among studies (Zhu, et al. 2003) , a large proportion of papillary carcinomas still remain that are negative for Ret rearrangements and for which the alternative molecular pathways need to be identified.
Moreover, a few studies have demonstrated Ret rearrangements in benign tumours associated with radiation exposure (Bounacer et al. 1997; Elisei, et al. 2001; Sadetzki, et al. 2004 ) and those without radiation history (Rhoden, et al. 2006) ; however, other studies have failed to substantiate these findings (Thomas et al. 1999) , adding further uncertainty to M a n u s c r i p t 6 the specific association of Ret rearrangement with papillary thyroid cancer. A recent paper by Port et al. (2007) has suggested a radiation signature consisting of seven genes which are differentially expressed in post-Chernobyl and sporadic PTC. However, caution is urged in the interpretation of this paper because the radiation-associated group was substantially younger than the control group and of a different ethnic origin, and detailed pathological information is lacking. The signature could therefore relate to variables inherent in the design of the study rather than specifically to radiation exposure.
In contrast to the association between the young onset, solid morphology of PTCs associated with Ret rearrangement, mutations in Braf show a different association with morphology. In the case of Braf the association is with older age at diagnosis and with a more classical PTC morphology. The frequency for Braf mutation varies in a number of studies from 36% to 69% in adult PTC (Cohen, et al. 2003; Kimura, et al. 2003; Powell, et al. 2005) . The frequency in post-Chernobyl cases (aged under 18 years at operation) is much lower: less than 10% (Nikiforova et al. 2004 ); and does not appear to be significantly different from that observed in sporadic cases of childhood thyroid papillary carcinoma (Lima, et al. 2004 ). This finding is perhaps not surprising as Braf and Ret oncogenic alterations appear to be virtually mutually exclusive in the series published thus far.
However, it is clear that all cases that are negative for Braf in young onset papillary cancer are not necessarily positive for Ret rearrangement, and that there are as yet unidentified oncogenic changes in these tumours. A novel rearrangement involving inversion of chromosome 7, resulting in fusion of part of the Braf gene with the Akap9 gene has also been described in three papillary carcinomas from young children in Belarus (Ciampi, et al. 2005) . However, further studies in age matched cases will be needed to establish whether this is a radiation-specific event or is related to age at diagnosis.
In contrast, FCs show a spectrum of DNA alterations that are different from PTCs. In particular, mutations of the H-ras and N-ras genes have been observed in FCs and follicular adenomas, but rarely in PTCs (Basolo, et al. 2000; Lemoine, et al. 1989; Manenti, et al. 1994; Namba, et al. 1990 ). The correct pathological assessment of the tumour is important in this distinction, as follicular variant PTCs can be misdiagnosed as FCs in some circumstances. In addition, the variation in frequency of Ras gene mutation in different series may be related to the differing techniques used in these older studies. A second common oncogenic alteration associated with FC and follicular adenoma is the translocation of peroxisome M a n u s c r i p t 7 proliferator activated receptor -Ppar -to the Pax8 gene promoter (Marques, et al. 2002) .
As observed with PTC, Ras gene mutation and Ppar /Pax8 are mutually exclusive in FC, suggesting that their major function in FC may be through the same pathway. Interestingly, rearrangements of Ppar correlated with younger age at diagnosis and Ras mutation with older age at diagnosis, suggesting that as with PTC, age at onset plays a major role in the molecular signature of the tumour . There are a number of other differences in gene expression that are associated with follicular cell neoplasia, but as this review focuses largely on alterations in DNA copy number, these are not reviewed here. chromosome-specific FISH karyotyping (Schrock, et al. 1997; Speicher, et al. 1996; Szuhai, et al. 2000) . This enables the identification of genomic copy number alterations (CNA) and structural chromosomal aberrations. A strong advantage of these techniques is that they do not require a prior knowledge of the alterations present in contrast to single-or multiplexprobe FISH techniques which target one or more genomic loci at the same time and can only be applied if genomic alterations such as copy number changes, inter-and intrachromosomal translocations or inversions are known.
For many decades G-banding of metaphases and subsequent karyotyping was the only approach to detect chromosomal changes. The application was limited by the requirement of an expert with a high level of expertise in cytogenetics, a need for high quality metaphase spreads and relatively low resolution which made smaller alterations undetectable. A vast improvement was attained by the invention of chromosome-specific FISH painting probes that label each chromosome with a specific colour or colour-mix. This makes inter chromosomal rearrangements identifiable by colour junctions of the FISH-painted rearranged chromosome. Three methods have been published for chromosome-specific fluorescence labelling -M-FISH (Speicher et al. 1996) , spectral karyotyping (Schrock et al. 1997 ) and COBRA-FISH (Szuhai et al. 2000) which mainly differ in the way of probe generation, image acquisition and computational classification of chromosomes. The best possible resolution that can be achieved with these techniques is about 2Mb (Speicher et al. 1996) and requires optimized metaphase spreads preparations.
A technique specially designed for scanning whole tumour genomes for genomic copy aberrations such as gains (duplications, amplifications) and losses (hemizygous -and homozygous deletions) is CGH (Kallioniemi et al. 1993) . It uses differentially fluorescencelabelled and fragmented reference and tumour DNA which is in situ co-hybridised to normal M a n u s c r i p t 9 metaphase spreads. During hybridisation fragments of reference and test DNA compete for complementary binding-sites presented by the normal metaphase chromosomes. The relative amounts of tumour DNA and reference DNA which bind a particular region on the metaphase chromosomes reflect copy number of the according region in the tumour genome. Gained regions are reflected by a tumour to reference fluorescence ratio larger than one and losses by ratios smaller than one. Since conventional CGH requires metaphase spreads the detection of CNA is typically limited to 10-20 Mb (Parente, et al. 1997 ).
The limitation of the low resolution of metaphase CGH has been overcome by replacing metaphases with DNA microarrays as hybridisation target (Solinas-Toldo, et al. 1997 ) and is appropriately named Array CGH (Figure 1 ). In addition to higher sensitivity, this technical improvement has several advantages such as higher potential throughput, and less amount of time from sample to result due to development in computer technology and bioinformatics which is needed to process the type of data produced. Moreover, an expertise of a cytogeneticist is not an absolute requirement. The first generation of DNA arrays for array CGH used large-insert clones such as BACs and PACs (Fiegler, et al. 2003; Pinkel, et al. 1998 ) giving a detection limit of 1Mb. Even though resolution of BAC arrays using a higher number of BAC clones was steadily increased and the advent of arrays using oligonucleotides as hybridisation targets (Carvalho, et al. 2004 ) has resulted in complete coverage of the genome with almost no gaps (Fiegler, et al. 2006 ), a majority of published array CGH studies used 1Mb BAC array CGH. This may be due to the fact that BAC arrays are relatively cheap, robust and applicable to DNA from formalin-fixed paraffin embedded A c c e p t e d M a n u s c r i p t 10 additionally can be used as translocation-specific probes for interphase-FISH on tissue samples. This strategy was used, for example, in human PTC to investigate the frequency and distribution of Ret/PTC rearrangements (Unger, et al. 2004 M a n u s c r i p t This also holds for thyroid follicular-cell neoplasia. The cytogenetic features of these tumours mainly depend on the type of thyroid cancer and partly allow distinguishing papillary, follicular and anaplastic cancers by characteristic genomic alteration patterns.
Cytogenetic alterations in thyroid follicular-cell neoplasia
Similar to other solid tumours, much more data on DNA copy number changes is published compared with the amount of data available on structural chromosome aberrations. This is due to the technical fact that identification of structural rearrangements only is feasible from primary short-term cultures but not from archived tumour tissues whilst genomic copy number analysis can be well done from both.
In papillary thyroid carcinomas (PTC), 10q rearrangements with breakpoints at 10q11.2 leading to an activation of the Ret oncogene were frequently found . Especially in radiation-associated PTC, several translocations have been reported which led to novel Ret activating fusion proteins (Corvi, et al. 2000; Fugazzola, et al. 1996; Klugbauer, et al. 1998; Klugbauer and Rabes 1999; Nakata, et al. 1999; Salassidis, et al. 2000 , reviewed by Santoro et al. (2006) ).
Chromosomal translocations and inversions with breakpoints at 1q22 were shown to activate another receptor tyrosine kinase, Trk and, just like Ret, was only seen in PTC Said, et al. 1994 ).
Since only a subgroup of PTC showed the above mentioned aberrations other studies which aimed to identify additional chromosomal abnormalities reported chromosomal breakpoints on 1p32-36, 1p11-13, 3p25-26 and 7q32-36 in PTC after conventional karyotyping (Roque, et al. 2001) . In primary cultures of radiation-associated thyroid tumours, novel breakpoints on chromosomes 4q, 5q, 6p, 12q, 13q and 14q were described by comprehensive analysis using M a n u s c r i p t 12 conventional and spectral karyotyping (Zitzelsberger, et al. 1999) . Spectral karyotyping also uncovered complex rearrangements in some tumours (Lu, et al. 2009; Weier, et al. 2006 )that have been investigated further by a BAC-FISH approach in order to delineate chromosomal breakpoints. In Figure 2 an example for fine-mapping of chromosomal breakpoints by FISH is shown for a case of a post-Chernobyl PTC.
Much more data on DNA copy number changes in PTC are available from which Table 1 summarizes the most commonly cited in the published literature. In a conventional CGH study on radiation-associated PTC the most frequent copy number changes reported were on chromosomes 2, 7q11.2-21, 13q21-22, 16, 20, 21 and 22 (Richter, et al. 2004 ) which was in accordance with the chromosome 22 changes reported in other studies (Hemmer, et al. 1999; Singh, et al. 2000) linking its presence to a widely invasive subtype of PTC. In addition, Kitamura et al. (2000) described an association of allelic losses of 1q, 4p, 9 and 16q with survival in PTC. More recent studies using array-CGH of specimen enriched for tumour cells by microdissection showed a more common appearance of copy number changes in PTC (Finn, et al. 2007; Unger, et al. 2008) . In these studies, recurrent aberrations were reported which are in accordance with previous CGH studies and which discriminate RET/PTC-positive and -negative tumours (Unger et al. 2008) or are typical for wildtype Ret or Braf tumours (Finn et al. 2007 ). In focal papillary carcinoma with changes in follicular-patterned thyroid nodules trisomy 17 was identified which potentially reflects a specific marker of this subset of thyroid lesions (Frau, et al. 2008 ). All these data on DNA copy number changes and structural chromosome aberrations in PTC suggest the existence of additional "driver"
aberrations beside the known gene alterations of the MAPK pathway (Ret, Braf).
Compared to PTC chromosomal changes are much more frequent in follicular and anaplastic thyroid carcinomas. In follicular thyroid carcinomas (FTC), cytogenetic abnormalities of chromosome 3 are characteristic changes (Herrmann, et al. 1991 ) and losses at 3p and of 3p25-pter in particular are the most common chromosomal aberrations in FTC (Roque, et al. 1993 ). Further CGH analysis of FTC defined three common regions of losses at 3p25-pter, 3p21, and 3q29-qter suggesting the involvement of more than one genomic region of chromosome 3 in follicular carcinogenesis. It is known that translocations with breakpoints at chromosome 3p25 lead to rearrangements of the gene Pparγ (Kroll, et al. 2000) . Other frequent copy number changes described in FTC are deletions of 1p, 6p/q, 8p/q, 9p, 11q, 13q, 18q, and 22q (Hemmer et al. 1999; Hemmer, et al. 1998; Roque, et al. 2003) . In Anaplastic thyroid carcinoma (ATC) is a rare but particularly aggressive tumour (Chiacchio, et al. 2008) . Surprisingly, the extent of DNA copy number changes does not directly correlate with the aggressiveness of tumours, when different histological types are compared. This is supported by the finding that only few ATC with an abnormal karyotype have been reported (Jenkins, et al. 1990; Mark, et al. 1987 ). More recently, advanced molecular cytogenetic approaches such as spectral karyotyping enabled the detection of numerous structural aberrations in ATC cell lines revealing chromosomal breakpoints at 1p36 and 17q24-25 which are novel in ATC as well as breakpoints at 3p21-22 and 15q26 which were described for well-differentiated thyroid cancers (Lee, et al. 2007 ). In contrast to this limited knowledge on structural chromosome aberrations in ATC, copy number changes were reported to greater extent. Recurrent chromosomal imbalances are gains of 1q and 20q which both were described in cell lines and in primary tumours (Lee et al. 2007; Miura, et al. 2003) . In another study gains and losses on chromosomes 8p and 8q as well as gains on 5p were regarded as typical changes which were rarely found in well-differentiated thyroid cancers (Wilkens, et al. 2000) . Overall, an increase in aberration complexity was reported for the progression from well-differentiated to poorly differentiated and anaplastic carcinomas. In contrast to Wilkens et al. (2000) chromosomal abnormalities of 5p15, 5q11-13, 19p/q (gains) and of 8p (loss) were regarded as common to all thyroid cancer types, whereas gains on 1p34-36, 6p21, 9q34, 17q25 and 20q as well as losses of 1p11-31, 2q32-33, 4q11-13, 6q21 and 13q21-31 were found only in poorly differentiated tumours and ATC (Wreesmann, et al. 2002) . In this study, recurrent gains of 3p13-14 and 11q13 and loss of 5q11-31 were reported as unique markers for ATC. Although there are coincidental findings A c c e p t e d M a n u s c r i p t 14 in these reports such as chromosome 20 abnormalities, a common issue with all of the studies on ATC seems to be the low number of cases studied (range: seven to 28 cases per study) which makes it difficult to identify specific recurrent aberrations.
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New candidate genes in thyroid cancer derived from chromosomal aberrations
As mentioned above a number of gene alterations are known in thyroid follicular-cell neoplasms. However, the reported gene alterations do not occur in all cases of a particular thyroid cancer type and, moreover, frequently show a heterogeneous distribution of alterations within the tumour (Ciampi and Nikiforov 2007; Unger et al. 2004; ). This was a strong motivation to search for gene alterations in thyroid follicular-cell neoplasia which interact with the known genetic changes or act as alternative drivers of tumourigenesis.
To address this question many studies used gene expression approaches, some of them combined with LOH analysis, for the detection of novel tumour suppressors or oncogenes.
In one of these studies this strategy resulted in the identification of the noncoding RNA gene, Nama, which is downregulated in PTC positive for B-raf mutation and associated with growth arrest (Yoon, et al. 2007 ). Another novel candidate gene associated with ATC is Plk1
(Polo-like Kinase 1) which was identified by expression microarray screening. It represents a serine/threonine kinase playing an important role in a number of G2-and M-phase-related events (Salvatore, et al. 2007) . It is of special interest that Plk1 was subsequently shown to represent a potential therapeutic target in ATC (Nappi, et al. 2009 ). In FTC overexpression of Akt1 and Akt2 as well as increased levels of total AKT activity has been reported (Ringel, et al. 2001 ). Other components of this pathway such as Pi3kca have been shown to be gained in copy number or mutated in both, FTC (Wu, et al. 2005) and ATC (Garcia-Rostan, et al. 2005 ). However, Akt activation which is linked to tumour progression (Guarino, et al. 2005; Vitagliano, et al. 2004 ) also plays a role in PTC tumourigenesis where RET/PTC rearrangements are associated with the expression of genes downstream of PI3K (Giordano, et al. 2005 ).
Another strategy to discover candidate genes involved in thyroid tumourigenesis is the usage of genomic approaches with chromosomal aberrations as the starting point. There are different molecular cytogenetic approaches to delineate chromosomal breakpoints. One BAC-FISH-based approach allows cloning of aberrations by using pools of uniformly labelled BAC clones covering a relatively large candidate region in the first place followed by a hybridisation with individual BAC probes labelled with individual dyes (Lu et al. 2009 ). This approach has been applied to a primary culture of post-Chernobyl thyroid tumours PTC in order to characterise chromosomal alterations on chromosome 9 (Weier et al. 2006) . In
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A c c e p t e d M a n u s c r i p t another study, the Thada gene, a putative death receptor-interacting protein, was identified with the same approach on chromosome 2p21 of a thyroid adenoma cell line (Rippe, et al. 2003) . After reduction of data complexity, results are correlated with pathomorphology, molecular biological status such as B-raf mutation status or Ret expression status.
As an extension to this strategy the effect of SNPs on gene expression and miRNA expression will also be examined, as this has already been shown to be important in thyroid cancer (Jazdzewski, et al. 2008) . The results are predicted to identify pathways that are important in thyroid carcinogenesis and provide data for future functional studies on novel genes in thyroid cancer. This project offers a new paradigm for cancer research in general, and highlights the future research possibilities of access to large numbers of quality assured biosamples which will become available to the research community as biobanking activity increases.
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Conclusion
It is evident from a large number of studies on thyroid follicular-cell neoplasia that chromosomal aberrations are good starting points for the search of novel cancer genes involved in tumourigenesis. Advanced molecular cytogenetic techniques facilitate this effort. It has been shown in this review that an integrative approach combining data from this genomic analysis with expression and clinical data is straight forward to identify genetic markers that may represent novel therapeutic targets in thyroid cancer.
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